Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A First-in-Human, Phase 1 Safety, Tolerability, Pharmacokinetic, and Preliminary Efficacy Study of Escalating Doses of ERX-315 in Participants With Advanced Solid Tumors

NCT06533332 is registered in ClinicalTrials.gov with EtiraRx Australia Pty Ltd as lead sponsor.

NCT NCT06533332
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06533332 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A First-in-Human, Phase 1 Safety, Tolerability, Pharmacokinetic, and Preliminary Efficacy Study of Escalating Doses of ERX-315 in Participants With Advanced Solid Tumors
Lead sponsor
EtiraRx Australia Pty Ltd
Phase
Phase 1
Overall status
Recruiting
Start date
October 14, 2024
Completion date
June 30, 2027
Enrollment
36 (estimated)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

advanced solid tumor, metastatic breast cancer, metastatic endometrial cancer, metastatic liver cancer, metastatic ovarian cancer, metastatic pancreatic cancer